SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 15, 2002
SALIX PHARMACEUTICALS, LTD.
-------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware
- --------------------------------------------------------------------------------
(State or other jurisdiction of incorporation)
000-23265 94-3267443
- ------------------------------------- --------------------------------------
(Commission file Number) (IRS Employer ID Number)
8540 Colonnade Center Drive, Suite 501, Raleigh, North Carolina 27615
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (919) 862-1000
----------------------------
Item 5. Other Events and Regulation FD Disclosure
Salix Pharmaceuticals, Ltd. issued two press releases today. The first
press release announced the implementation of strategic modifications to its
leadership structure.
The second press release announced that it has in-licensed rights to a
pellet formulation of Mesalamine, used for the treatment of acute episodes and
the maintenance of remission of ulcerative colitis, under an agreement with Dr.
Falk Pharma GmbH (Frieburg, Germany).
Both of these press releases are attached as exhibits.
Item 7. Financial Statements and Exhibits
(c) Exhibits
99.1 Press Release dated July 15, 2002
99.2 Press Release dated July 15, 2002
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
SALIX PHARMACEUTICALS, LTD.
Date: July 15, 2002 By: /s/ Adam C. Derbyshire
--------------------------------
Adam C. Derbyshire
Vice President and Chief Financial Officer